[Source: Open Forum Infectious Diseases, full page: (LINK). Abstract, edited.]
Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
Deepika Slawek, Diana Altshuler, Yanina Dubrovskaya, Eddie Louie
Open Forum Infectious Diseases, Volume 4, Issue 4, 1 October 2017, ofx184, DOI: https://doi.org/10.1093/ofid/ofx184
Published: 07 October 2017 – Received: 18 May 2017 – Accepted: 30 August 2017
Citation: Deepika Slawek, Diana Altshuler, Yanina Dubrovskaya, Eddie Louie; Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients, Open Forum Infectious Diseases, Volume 4, Issue 4, 1 October 2017, ofx184, https://doi.org/10.1093/ofid/ofx184
© 2017 Oxford University Press
Abstract
Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.
Issue Section: Brief Report
–
Keywords: Tigecycline; Legionellosis.
——-